Search the blog...

Home

About

Contact

Switch blog

Thoughts from the Centre

The Future of Health in Europe: digital, equitable, sustainable

Posted on 3/11/2023 | 0 Comments





Healthcare systems in Europe face substantial challenges, such as ageing populations, changing public expectations, scarcity of healthcare professionals, rising health inequalities, rigid and complex financing models, and an increasing cost of innovation. Since 2017, Deloitte have run a global Future of Health campaign that believes that, by 2040, digital disruption enabled by interoperable data, AI, open and secure platforms, behaviour change, and technological and scientific breakthroughs, will shift the ubiquitous, reactive treatment model to a proactive, preventative one built around empowered citizens. This shift has the potential to realise better health outcomes and improve the cost-effectiveness of service delivery and is relevant to health systems everywhere. Our blog this week highlights the findings in our report, The Future of Health in Europe, and how Deloitte's global vision could be used to chart Europe's healthcare future.


Why does Europe need a new healthcare vision?

Europe has a rich history of innovation in science and technology and is a significant player in the global economic landscape. However, each country is responsible for its own healthcare, resulting in a tapestry of distinct systems moulded by their cultural, economic and political history. Healthcare funding comes from a mix of government schemes, social health insurance and private health insurance. Although most countries aspire to Universal Health Coverage (UHC), there is a wide variation in: the range of services offered, the proportion of GDP funding and per capita spend on healthcare, and the degree of cost sharing. European pricing and reimbursement models also vary, meaning access to new medicines and technologies differ.

The COVID-19 pandemic exacerbated many of the existing challenges affecting healthcare in Europe, exposing deep structural issues, disrupting services and placing an already beleaguered workforce under unrelenting strain. While there was an acceleration in technology-enabled solutions, including telehealth, most countries had to increase healthcare expenditure considerably. Since 2021, the deteriorating economic outlook has added further complexities, requiring most European countries to look for more sustainable and resilient healthcare models to tackle the challenges faced and rising health inequalities. Indeed, the European Commission has established a Recovery and Resilience facility and launched a new EU Global Health Strategy focused on digitalisation, improving the sustainability of the HCP workforce, 'greener' health systems, and a greater emphasis on primary care and prevention while giving citizens access to and control over their health data.

The present moment is therefore pivotal for European countries to reimagine their healthcare business and operating models and prepare for the future, including shifting to a proactive healthcare system focused on health promotion, prevention and delaying and managing symptoms (Figure 1). Moreover, we believe that Deloitte's vision for the Future of Health is relevant to all European countries, although the rate at which each country realises this future will vary.


Figure 1: Healthcare expenditure on sick care will shift towards more health promotion and prevention



What will European healthcare look like by 2040?

By 2040, and sooner in some countries, we expect that advances in diagnostics and scientific breakthroughs, an emphasis on prevention over cure, a holistic understanding of wellness, and adoption of Al-enabled technologies, data sharing and interoperability, will have transformed the European healthcare ecosystem, supported by political and financial commitments by governments (including the European Union). Healthcare will be population based, predictive, preventative, participatory, personalised and precise (5P health) - and will have embedded the quintuple aims of health (see Figure 2).

Figure 2: By 2040 health systems will have reorientated themselves around the quintuple aims as part of a citizen-centric, data-driven healthcare system



Shifting to this future model has the potential to reduce the current trajectory of healthcare costs while improving health outcomes. Our modelling of this shift suggests that by 2040 a higher proportion of revenue will target health promotion, prevention and health restoration (increasing from 17 per cent in 2019 to 51 per cent in 2040). A much lower proportion will be needed for sickness treatment and symptom management (from 83 per cent in 2019 to 49 per cent in 2040). In altering Europe's expected cost curve, the 'wellbeing dividend' could be €250 billion by 2030 and €595 billion by 2040.

What does this future mean for incumbents in the health system?

Presently, incumbents (hospitals, other healthcare providers, payers, HCPs and life sciences companies) are focussed mainly on sick care. The Future of Health will require new business models, with new entrants capturing a growing share of the market, heralding a radical transformation. Changes include: the end of large acute, treatment-focused general hospitals; pharmaceutical companies focussed more on precise, targeted treatments underpinned by outcome-based investment models; and funding in general

transitioning from activity-based to outcome-based models targeted at achieving healthcare's quintuple aim.

What are the catalysts for a shift to the Future of Health in Europe?

All European healthcare systems, despite their diversity, have the potential to realise the Future of Health although the pace of transformation will vary. Presently, this shift is being shaped by macro market dynamics (the pandemic, inflation, climate change, health equity and a shrinking global HCP workforce. Furthermore, there are nine specific drivers (see Figure 3). We contend that five of these drivers: empowered consumer, data sharing, continued innovation, data interoperability and networks and ecosystems - are unstoppable. The other four, risk decelerating progress, unless more affirmative intervention and leadership at a national /system level is provided.




Figure 3. The impact of macro market dynamics and health drivers on the future of health

The main interventions needed to these four drivers to optimise progress include:

- **Development of institutional trust/social compact**: trust substantially shapes people's belief, and willingness to participate in screening, vaccination programmes, health checkups, and healthier lifestyles. However, trust in healthcare institutions varies considerably and is lowest in people who have experienced discrimination (such as age, ethnicity, gender and socio-economic). This group are also at higher risk of poor health. Stakeholders need to enhance transparency and adopt responsible policies to mitigate social and economic inequities and foster trusted relationship with citizens.
- **Behaviour change/nudging**: altering individuals' health-related behaviours and improving prevention is difficult. Individuals in higher socio-economic groups tend to have better health literacy and be willing to spend to improve their health; while those in lower socio-

economic groups have poorer health literacy and limited resources to spend on well-being. Evidence-based cross-government actions, incentives, taxes and regulations can 'nudge' people to make better choices, alongside support from peer groups, employers and local charities.

- Platforms and hypercompetition: platform-based, technology-enabled, interactions
 between citizens and healthcare stakeholders will accelerate healthcare's future, as
 citizens demand more price transparency and wellness-focused, end-to-end healthcare
 interventions. These platforms facilitate information sharing and goods and services
 exchange among stakeholders, enabling them to co-create goods and services with lower
 capital costs. They also enable citizens to compare offerings, improve choice and
 experience.
- Sick-care to well-care: committed leadership and new funding models are needed to
 challenge entrenched attitudes and increase the pace of change from treatment-centred
 care to a preventative, primary care, population health led, integrated system. This
 requires change management; enabled by AI, alongside digital and genomic tools, digitally
 mature, interoperable data systems, and a collaborative environment focused on quality
 improvement.

What can European healthcare stakeholders do to stay relevant?

Currently, organisations are mostly siloed and operate independently. However, an explosion in health data, analytics and consumerisation are attracting new entrants, disrupting the existing, rigid ecosystem, and providing new access routes. In the future, healthcare will be organised around an empowered consumer, providing a network of stakeholders forming partnerships and collaborations. These changes will redefine traditional roles and require all stakeholders to adapt their operating models. Incumbents can either lead the way or resist change and lose their market share. Figure 4 details actions for stakeholders to help them survive and thrive.

Figure 4. Future of Health priorities for incumbents, new entrants, and non-native industry entrants

Industry incumbents Classic industry players (providers, payers, pharma, medtech)	New entrants Emergent players within the industry (e.g., health tech, consumer health)	Non-native industry entrants Established players entering health (i.e., tech hyperscalers, retail)
Execute digital transformation that enables incumbents to engage with newly empowered citizens, earning their trust and demonstrating value Continue to invest in a lean digital core, such as process re-engineering and foundational technology that enables automation and analytics Establish enterprise-wide data and insights generation platforms by migrating systems to the cloud (e.g., EMR, supply chain, HR) Implement new skills and ways of working, novel recruitment and retention initiatives and augment the workforce through technology Deploy innovative operating processes and funding models underpinned by the design, test, and scale of products, services and offerings Access next-gen tech and capabilities through acquisitions, partnerships, alliances and networks. Ensure leaders have a digital first mindset and change management skills	Develop go-to-market channels with a hyperfocus on citizen engagement, recruitment and retention Build infrastructure that enables collaboration (e.g., ecosystems, alliances, partnerships) with high-value industry players (commercial and government) Invest in enterprise technology that allows for rapid growth and scalability Adopt a security and sustainability by design approach to innovation The essentially human traits such as empathy, communication, persuasion, problem-solving, judgement and strategic decision making will be more valuable skills for the workforce than ever Bring new opportunities for investment and flexible funding of consumer health including investors focused on AgeTech and FemTech embracing the principles of VBHC	Build infrastructure that enables collaboration (e.g., ecosystems, alliances, partnerships) with high-value industry players (commercial and government.) Design and deploy health-specific marketing, sales, and CX campaigns and capabilities to gain brand credibility/permission Optimise and adapt technology systems (e.g., regulatory, cybersecurity) that support health-specific ventures/use cases Expand management & human capital capabilities to effectively navigate regulated, multi-stakeholder health ecosystem Introduce innovative contracting and value-based funding models at scale Build new businesses to respond to the changing incidence and prevalence of major chronic diseases with input from the newly empowered citizens

Conclusion

Source: Deloitte analysis, 2023.

By 2040, if our projections hold, the healthcare industry will be radically different, significantly extending quality of life and bringing profound changes to the entire healthcare ecosystem. Incumbents and new entrants will work together to deliver equitable, sustainable, resilient, and affordable healthcare for all European citizens. Although European countries are at different points of their journey, most are reevaluating their health systems propelled by a political commitment to improve health equity and reduce inequalities. Our report provides a vision of how this can be achieved and actions for stakeholders to implement. In charting their path to this future, each country will need to establish a citizen-centred, technology-empowered infrastructure and a healthcare system that has transitioned from being activity-based to value-based, aligning incentives with the quality of health outcomes.



Karen Taylor - Director, UK Centre for Health Solutions

Karen is the Research Director of the Centre for Health Solutions. She supports the Healthcare and Life Sciences practice by driving independent and objective business research and analysis into key industry challenges and associated solutions; generating evidence based insights and points of view on issues from pharmaceuticals and technology innovation to healthcare management and

reform.

Email | LinkedIn



Márcia Costa - Manager, Centre for Health Solutions

Márcia is the research manager for healthcare in the Centre for Health Solutions, providing support and expertise to develop solutions to overcome today's healthcare challenges. Working with the team, Márcia develops insights based on rigorous data analysis to improve outcomes for patients and increase health systems efficiencies. Originally from Portugal, Márcia has an MSc in biomedical engineering and biophysics and a PhD in cancer research. Márcia has previously worked in publishing for an oncology journal in London. Márcia is passionate about health equity.

Email | LinkedIn

Comments

You can follow this conversation by subscribing to the comment feed for this post.

Verify your Comment Previewing your Comment

Posted by: |

This is only a preview. Your comment has not yet been posted.

Post Edit



Your comment could not be posted. Error type:

Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.
Continue
Post a comment
Comments are moderated, and will not appear until the author has approved them.
If you have a TypeKey or TypePad account, please Sign In
(URLs automatically linked.)
Your Information
(Name and email address are required. Email address will not be displayed with the comment.)
Name

Regulatory

Pharmaceuticals

	Please	e enter a valid en	nail address			
	Web S					
	Invalid	d URL				
		Post	Preview			
8 * 8 ⊞ © _m ©						
Breast cancer av				ions for th	e over-t	nsolidated: he-counter nes' market
Categories						
Biotechnology	Diseases	Healthcare	Medical Devices	Mental	health	

Sign up to receive latest blogs, thought leadership and email updates

Name			
Email *			

Subscribe

Company *		
Job title *		
See our privacy policy		

Posts from @DeloitteUK Follow on X **Deloitte UK** 🙋 🗌 @DeloitteUK · Mar 21, 2023 We are proud to join The Princess of Wales' Business Taskforce for Early Childhood. Building on Deloitte's long-standing commitment to children and young people, through mental health, literacy, confidence and school leadership. **#ShapingUs** The Prince and Princess @ @Kensingt · Mar 21, 2023 #ShapingUs is all about the societal impact we can have to transform lives for generations to come. Today we launched the Business Taskforce ... (i) Q 32 \Q 2.2K It's time for businesses to prioritise early childhood. Our report for @Earlychildhood shows investing in early childhood could generate £45.5 billion in value for the national economy each year, and help create a healthier, happier society.

Subscribe to the blog

Deloitte UK Centre for Health

Solutions

© 2024. See **Terms of Use** for more information.

Deloitte LLP is the United Kingdom affiliate of Deloitte NSE LLP, a member firm of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"). DTTL and each of its member firms are legally separate and independent entities. DTTL and Deloitte NSE LLP

do not provide services to clients. Please see **About Deloitte** to learn more about our global network of member firms.

Deloitte LLP is a limited liability partnership registered in England and Wales with registered number OC303675 and its registered office at 1 New Street Square, London EC4A 3HO, United Kingdom.

Accessibility statement